Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Standard interferon showed no clear difference in relapse(recurrence after stopping intervention) compared with placebo or control (low certainty).
Standard interferon probably leads to higher end‐of‐treatment response compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in sustained virological response 6 months after stopping treatment compared with placebo or control (moderate certainty).
The review found no eligible studies for this question.
Direct antivirals (grazoprevir and elbasvir) may leads to higher end‐of‐treatment response compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).
Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in all‐cause death ( compared with placebo (moderate certainty).
It is very uncertain whether cerebrolysin or Cerebrolysin‐like agents changes non‐death attrition compared with placebo (very low certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with SAEs** compared with placebo (moderate certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with adverse events, compared with placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Angiotensin‐converting enzyme inhibitors showed no clear difference in death (any cause) compared with placebo (low certainty).
Angiotensin‐converting enzyme inhibitors showed no clear difference in CVD events: total (fatal and non‐fatal) compared with placebo (low certainty).